Background: The global pharma sector is fast shifting from generics to biologics and
biosimilars with the first approval in Europe in 2006 followed by US approval in 2015. In the …

We use a comprehensive database of venture-capital-backed companies from China to test
whether and how foreign venture capitalists (VCs) can facilitate international initial public …

Background Global healthcare innovation networks nowadays have expanded beyond
developed countries with many developing countries joining the force and becoming …

Abstract Research Summary Venture capital (VC) firms predominantly source investments
from local networks within tight geographic bounds. Against that tendency, VCs are …

China's healthcare system is experiencing significant growth from expanded government-
backed insurance, greater public-sector spending on hospitals, and the introduction of …

This paper examines the development of biotech in Shanghai using the perspective of
regional innovation system (RIS). Three important components of RIS, namely land, human …

Abstract Objectives The United States and China are broadening health insurance coverage
and increasing spending on pharmaceuticals, in contrast to other major economies that are …

Breakthroughs in biotechnology, globalizing intellectual property rights legislations, and
growing venture capital in the past thirty years have given rise to new forms of capitalist …

Stages of drug (and vaccine) discovery and evaluation that involve laboratory animals
increasingly occur via scientific collaborations across national borders and continents. Many …

Background: This article sets up the initial discussion of the evolution of biopharmaceutical
innovation in China through the perspective of sectoral innovation system (SIS). Methods …